Long-term oncologic outcomes of radical prostatectomy compared with brachytherapy-based approaches for intermediate- and high-risk prostate cancer - Abstract

PURPOSE: To review the recently published contemporary long-term outcomes from tertiary care urologic practices comparing brachytherapy-based management strategies and radical prostatectomy (RP) across intermediate- and high-risk groups.

METHODS AND MATERIALS: Literature was reviewed for the past 5 years under the search terms localized prostate cancer, outcomes, brachytherapy, and adical prostatectomy. Abstracts were reviewed and excluded if results were not reported according to the recognized risk groupings or if followup was less than 5 years.

RESULTS: A total of 1237 abstracts concerning adical prostatectomy and 600 concerning brachytherapy were retrieved in the initial search. Of these, 80 met the inclusion criteria, and the articles were retrieved and reviewed in detail.

CONCLUSIONS: For intermediate- and high-risk prostate cancer, brachytherapy-based approaches provide superior long-term oncologic and functional outcomes. Irritative and obstructive symptoms are prominent in the first 6-12 months but resolve by 3 years for all but < 5%. High-risk patients do very well with multimodality treatment combining external beam radiotherapy, a brachytherapy boost, and androgen deprivation for 9-12 months.

Written by:
Crook J.   Are you the author?
Department of Radiation Oncology, British Columbia Cancer Agency, Center for the Southern Interior, Kelowna, BC, Canada.

Reference: Brachytherapy. 2014 Sep 22. pii: S1538-4721(14)00639-4.
doi: 10.1016/j.brachy.2014.08.047


PubMed Abstract
PMID: 25255713

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe